UBS Group Cuts IQVIA (NYSE:IQV) Price Target to $255.00

IQVIA (NYSE:IQV) had its target price trimmed by UBS Group from $260.00 to $255.00 in a report published on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

IQV has been the topic of a number of other reports. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Finally, BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Stock Performance

Shares of IQV opened at $208.13 on Friday. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The company has a market capitalization of $37.78 billion, a PE ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48. The company’s 50 day moving average price is $200.67 and its 200 day moving average price is $219.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA will post 10.81 EPS for the current fiscal year.

Insider Activity

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new stake in IQVIA during the second quarter valued at $803,000. Czech National Bank lifted its stake in shares of IQVIA by 1.6% in the 3rd quarter. Czech National Bank now owns 35,279 shares of the medical research company’s stock valued at $8,360,000 after purchasing an additional 559 shares during the period. GAMMA Investing LLC grew its stake in IQVIA by 36.1% during the third quarter. GAMMA Investing LLC now owns 1,101 shares of the medical research company’s stock worth $261,000 after purchasing an additional 292 shares during the period. Wedmont Private Capital increased its holdings in IQVIA by 9.5% in the third quarter. Wedmont Private Capital now owns 2,042 shares of the medical research company’s stock worth $460,000 after purchasing an additional 178 shares in the last quarter. Finally, Bruce G. Allen Investments LLC lifted its stake in IQVIA by 1,013.6% in the third quarter. Bruce G. Allen Investments LLC now owns 245 shares of the medical research company’s stock valued at $58,000 after buying an additional 223 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.